June 13, 2017 / 12:17 PM / in 6 months

BRIEF-Braeburn Pharma submits application to market opioid implant in Canada

June 13 (Reuters) - Knight Therapeutics Inc

* Braeburn pharmaceuticals and knight therapeutics announce filing of new drug submission for probuphine(r) in canada for opioid drug dependence

* Knight therapeutics - been accepted for review by health canada for probuphine (buprenorphine subdermal implant) for treatment of opioid drug dependence Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below